Protocols for Prevention of PPH During CS in High Risk Group

Assiut University

Status: Unknown

Conditions: Atonic PPH

Treatments: Drug: Syntocinon, papal, misotac

Study type: Observational

Funder types: Other

Identifiers

NCT05099575

Atonic PPH in high risk group

Details and patient eligibility

About

PPH is one of the most leading causes of maternal mortality,. It means loss of 500 ml blood after vaginal delivery and 1000 ml blood after cesarean delivery. Although it's preventable it represents about 27%of maternal deaths. Atony is the main cause of PPH. 70%of PPH corresponds to uterine atony. Uterotonics like oxytocin, misoprostol, ergometrine, carbetocin and combinations of these drugs can be used but until now there is no agreement on medication that can be the most effective.

Enrollment: 448 estimated patients

Sex: Female

Ages: 19 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 1. Pregnant full term>37 w 2. Maternal age 19- 40 3.physical state 1&2 4.patient willing to enter the study

Exclusion criteria

• 1.who refuse to participate in study 2.immunocomprmized and patients who had contraindicated from any of drugs used 3.patients with hypersensitivity to any drug

Trial design

448 participants in 4 patient groups

Pregnant women who receive oxytocin

Treatment:

Drug: Syntocinon, papal, misotac

Pregnant Women who receive carbetocin

Treatment:

Drug: Syntocinon, papal, misotac

Pregnant women who receive misoprostol

Treatment:

Drug: Syntocinon, papal, misotac

Pregnant women who receive ergometrine

Treatment:

Drug: Syntocinon, papal, misotac